ITOS — iTeos Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $387.11m
- -$144.81m
- $12.60m
- 51
- 24
- 49
- 36
Annual income statement for iTeos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 345 | 268 | 12.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 28 | 45.2 | 99.9 | 141 | 164 |
| Operating Profit | -28 | -45.2 | 245 | 126 | -151 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22.3 | -38.1 | 256 | 149 | -109 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -22.5 | -38 | 215 | 96.7 | -113 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.5 | -38 | 215 | 96.7 | -113 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -26.5 | -43.4 | 215 | 96.7 | -113 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.797 | -1.24 | 5.68 | 2.56 | -3.15 |
| Dividends per Share |